131.87
0.00 (0.00%)
| Previous Close | 131.87 |
| Open | 131.90 |
| Avg. Volume (3M) | 2,731,608 |
| Market Cap | 14,047,055,872 |
| Price / Earnings (Forward) | 158.73 |
| Price / Sales | 19.89 |
| Price / Book | 12.15 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -10.97% |
| Operating Margin (TTM) | -14.65% |
| Diluted EPS (TTM) | -0.720 |
| Quarterly Revenue Growth (YOY) | 50.80% |
| Total Debt/Equity (MRQ) | 1.48% |
| Current Ratio (MRQ) | 6.36 |
| Operating Cash Flow (TTM) | -73.18 M |
| Levered Free Cash Flow (TTM) | -63.55 M |
| Return on Assets (TTM) | -6.96% |
| Return on Equity (TTM) | -8.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Intra-Cellular Therapies Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 0.0 |
| Average | -1.50 |
|
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.27% |
| % Held by Institutions | 96.54% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |